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The effect of serum triglyceride 
concentration on the outcome 
of acute pancreatitis: systematic 
review and meta-analysis
Lóránd Kiss1, Gabriella Fűr1, Péter Mátrai2, Péter Hegyi2,9, Emese Ivány3, 
Irina Mihaela Cazacu2, Imre Szabó4, Tamás Habon  5, Hussain Alizadeh6, Zoltán Gyöngyi7, 
Éva Vigh8, Bálint Erőss2, Adrienn Erős2, Máté Ottoffy2, László Czakó3 & Zoltán Rakonczay Jr.1
Elevated serum triglyceride concentration (seTG, >1.7 mM or >150 mg/dL) or in other words 
hypertriglyceridemia (HTG) is common in the populations of developed countries. This condition is 
accompanied by an increased risk for various diseases, such as acute pancreatitis (AP). It has been 
proposed that HTG could also worsen the course of AP. Therefore, in this meta-analysis, we aimed to 
compare the effects of various seTGs on the severity, mortality, local and systemic complications of AP, 
and on intensive care unit admission. 16 eligible studies, including 11,965 patients were retrieved from 
PubMed and Embase. The results showed that HTG significantly elevated the odds ratio (OR = 1.72) for 
severe AP when compared to patients with normal seTG (<1.7 mM). Furthermore, a significantly higher 
occurrence of pancreatic necrosis, persistent organ failure and renal failure was observed in groups with 
HTG. The rates of complications and mortality for AP were significantly increased in patients with seTG 
>5.6 mM or >11.3 mM versus <5.6 mM or <11.3 mM, respectively. We conclude that the presence of 
HTG worsens the course and outcome of AP, but we found no significant difference in AP severity based 
on the extent of HTG.
Triglyceride is a component of lipoproteins, and its reference range in the blood serum is below 1.7 mM (150 mg/dL). 
Nowadays, a high-fat diet and resultant obesity are common; therefore, the prevalence of elevated serum triglycer-
ide concentration (seTG) is high, affecting approximately 27% of all adults1. In the disease of hypertriglyceridemia 
(HTG), the fasting seTG exceeds 1.7 mM. The aetiology of HTG may be primary (caused by genetic mutations), 
but it is most commonly secondary2. The causes of secondary HTG include obesity, unhealthy diet or lifestyle 
(such as heavy alcohol consumption), pregnancy, hypothyroidism, hepatic steatosis, nephrotic syndrome, type-2 
diabetes mellitus, and some drugs (e.g. glucocorticoids, oestrogen and tamoxifen)2,3. The extent of HTG has been 
classified by the Endocrine Society into the following groups based on fasting seTG: mild (1.7 to 2.3 mM), mod-
erate (2.3 to 11.2 mM), severe (11.3 to 22.4 mM) and very severe HTG (>22.4 mM)4. However, the classifica-
tion of HTG based on fasting seTG was somewhat different according to the National Cholesterol Education 
Program Adult Treatment Panel III guideline5. They specified borderline-high seTG from 1.7 to 2.2 mM, high 
seTG between 2.2 and 5.6 mM, and very high seTG above 5.6 mM. HTG is associated with different comorbidi-
ties. In the general population, people with moderate or severe non-fasting seTG compared with individuals with 
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non-fasting seTG in the normal range have a significantly higher risk for ischemic heart disease, ischemic stroke 
and mortality1. HTG is also an important risk factor for the development of acute pancreatitis (AP)6.
AP is a sudden inflammation of the pancreas that lasts for a short period (from days to some weeks)6. The 
severity of the disease can be classified into three groups based on the modified Atlanta criteria: mild, moder-
ately severe and severe7. Moderately severe and severe forms of AP are associated with various local and systemic 
complications which also influence the rate of mortality. Necrosis, infections, abscesses and/or pseudocysts can 
occur in the pancreas. AP may also cause systemic complications, such as sepsis, systemic inflammatory response 
syndrome, and transient or persistent organ failure7–9. Organ failure most commonly affects the lungs, kidneys and 
cardiovascular system. About 60–80% of AP cases are due to massive alcohol consumption and gallstone disease, 
whereas 1–9% of the cases are HTG-induced2,6,10. In pregnancy, up to 56% of AP cases are HTG-related2. It is widely 
accepted that severe HTG markedly increases the risk for AP2,11. However, some authors define HTG-induced AP 
(HTG-AP) when seTG is >5.6 mM10. There is no significant evidence for HTG-AP at <5.6 mM seTG12. Beyond 
the increased risk for AP in severe HTG, previous publications have indicated that there is a relationship between 
seTG and the severity of AP10,13,14, even in the case of mild or moderate HTG15–18. Nawaz et al.15 reported that HTG 
independently and proportionally correlates with persistent organ failure regardless of AP aetiology. Zeng et al.16 
showed that seTG >2.26 mM increases the risk for systemic and local complications in acute biliary pancreatitis. 
However, some studies have shown no relationship between seTG and the severity of AP19,20. To clarify this dis-
crepancy, earlier efforts have aimed to analyse the effect of seTG on the severity of AP through meta-analyses10,13,14. 
Only one meta-analysis has been published in which the authors investigated the effect of seTG on the outcomes of 
AP13. However, the groups of patients classified by seTG overlapped, which is a significant limitation of that study.
To the best of our knowledge, there is no meta-analysis where the effect of several different and well-defined 
seTGs have been investigated on the course of AP. Therefore, our aim was to evaluate and compare the effects of 
normal seTG with the effect of mild, moderate and severe HTG on the severity, mortality and other complications 
of AP. In addition, various ranges within the HTG were compared.
Methods
This systematic review and meta-analysis was conducted according to the protocol previously registered in the 
PROSPERO database (https://www.crd.york.ac.uk/PROSPERO/, ID: CRD42017071264). The methodology for 
this analysis followed recommendations by Stroup et al.21 and the guidelines for the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis Protocols (Supplementary Table S1)22. The analysis was based on the 
Problem, Intervention, Comparison intervention, and Outcome (PICO) model22. The problem was AP. The inter-
vention was HTG with various groups formed for the analysis: >1.7, 1.7–5.6, 1.7–11.3, >5.6 and >11.3 mM 
Figure 1. Flow diagram for article selection.
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First author, year Source Country
Study 
design
Inclusion 
period Centre
Patient 
number: 
used for 
analysis/
total (n/n) AP aetiology
AP severity 
classification 
system
Groups 
based 
on seTG 
(mM); 
patients 
(n) AP outcomes
Jiang, 200554 Chin J Dig Dis CHN NA Jan 2000–Jan 2002 S 99/99 B, A, O N.R.
<1.7; 71
>1.7; 28
# Hospital stays
# Ranson and APACHE 
II scores
# Pulmonary, 
cardiovascular and renal 
failure
# Pancreatic pseudocyst 
and infected necrosis
Balachandra, 200620 Int J Clin Pract UK P 2001 S 40/43 B, A, I, pE N.R. <1.8; 26>1.8; 14
# Pancreatic pseudocyst 
or necrosis
# Respiratory 
insufficiency
# Atlanta mild and severe 
cases
Deng, 200855 World J Gastroenterol CHN R
Mar 2003–
Dec 2004 S 176/176
A, B, D, L-asparaginase 
chemotherapypregnancy N.R.
<5.65; 131
≥5.65; 45
# Ranson, APACHE II 
and Balthazar’s CT scores
# Pulmonary (ARDS) 
and renal failure
# Acute hepatitis
# Shock
# Encephalopathy
# Infection
# Mortality
Baranyai, 201256 Clin Lipidol HUN R Jan 2007–Dec 2009 S 351/351 HTG, O N.R.
<11.3; 328
>11.3; 23
# Complications
# Severe AP
# Sepsis
# Necrosis
# Mortality
# Hospital stays
Ivanova, 201257 Hepatobiliary Pancreat Dis Int ESP P
Mar 2006–
Feb 2007 S 133/133 B, A, I, HTG, O N.R.
<11.28; 
126
>11.28; 7
# ICU admission
# Mortality
# Hospital stays
Zeng, 201416 Am J Med Sci CHN R N.D. S 340/340 B, B + HTG
Revised 
Atlanta 
Classification
<1.70; 250
1.70–2.25; 
18
2.26–5.64; 
31 ≥ 5.65; 
41
# Mild, moderately 
severe and severe AP
# Ranson score
# Pulmonary, 
cardiovascular and renal 
failure
# Pancreatic pseudocyst 
and infected necrosis
# Sepsis
# SIRS
# Pancreatic necrosis, 
pseudocyst and abscess
Nawaz, 201515 Am J Gastroenterol USA P
Jun 2003–
Jun 2004 S 201/201 B, A, I, HTG, O
Revised 
Atlanta 
Classification
<1.70; 115
1.70–2.26; 
20
2.27–11.32; 
41
≥11.33; 25
# Persistent organ failure
# ICU admission
# Mortality
# Pancreatic necrosis
Zheng, 201558 Pancreas CHN R Jan 2006–Dec 2010 M 2461/2461 B, A, HTG, O N.R.
<11.3; 
2206
>11.3; 255
# Mild and severe AP 
cases
# Mortality
Chen, 201642 Pancreatology CHN NA Mar 2015–Mar 2016 S 57/57 B, A, I, HL
Revised 
Atlanta 
Classification
<11.33; 30
>11.33; 27
# Mild, moderately 
severe and severe AP 
cases
# Pancreatic necrosis
# Organ failure, multiple 
organ dysfunction 
syndrome
# Infected necrosis
# Mortality
# Length of 
hospitalization
# Length of ICU stay
# APACHE II, SOFA and 
BISAP scores
Goyal, 201643 North Am J Med Sci USA R
Jan 2009–
Jun 2015 S 177/177 HTG, A
Revised 
Atlanta 
Classification
<11.33; 
147
>11.33; 30
# Mild, moderately 
severe and severe AP 
cases
# BISAP, SIRS scores and 
Balthazar index
# Hospital stays, ICU 
admission
# Surgical intervention
# Mortality
Continued
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First author, year Source Country
Study 
design
Inclusion 
period Centre
Patient 
number: 
used for 
analysis/
total (n/n) AP aetiology
AP severity 
classification 
system
Groups 
based 
on seTG 
(mM); 
patients 
(n) AP outcomes
Párniczky, 2016*,44 PLoS One HUN P Jan 2013–Jan 2015 M 113/600 B, I, A, A + D, HL, pE, O
Revised 
Atlanta 
Classification
<1.7; 59
1.7–5.64; 
28
5.65–11.33; 
4
≥11.33; 22
# Mild, moderately 
severe and severe AP 
cases
# Mortality
Tai, 201645 Gastroenterol Res Pract CHN R
Feb 2010–
Jan 2014 S 294/294 B, HTG
Revised 
Atlanta 
Classification
<11.33; 
168
>11.33; 
126
# Mild, moderately 
severe and severe AP 
cases
# Mortality
# Pulmonary failure 
(ALI/ARDS)
# Renal insufficiency
# Cardiovascular 
insufficiency
# Gastrointestinal 
bleeding
# Sepsis
# Multiple organ 
disfunction syndrome
# Hospital stays
Sue, 201717 Pancreas USA R 2006–2013 M 2519/2519 B, A, O
Revised 
Atlanta 
Classification
<1.7; 1729
1.7–2.26; 
251
2.27–5.66; 
308
5.67–11.32; 
82
≥11.33; 
149
# No organ failure
# Transient organ failure
# Multiple or persistent 
organ failure
Wan, 201718 Lipids Health Dis CHN R
Jan 2005–
Dec 2013 S 1539/1539 B, A, HTG, I, O
Revised 
Atlanta 
Classification
<1.7; 1078
1.7–2.23; 
107
2.23–11.2; 
242
>11.2; 112
# Mild, moderately 
severe and severe AP 
cases
# Pancreatic necrosis
# Organ failure, 
persistent or multiple 
organ failure
# Persistent SIRS
# Mortality
# Length of 
hospitalization
# Length of ICU stay
# Acute peripancreatic 
fluid collection
# Acute necrotic 
collection
Wu, 201746 Pancreatology CHN R Jul 2009–Jul 2014 S 262/262 B, A, O
Revised 
Atlanta 
Classification
<1.7; 104
1.7–5.67; 
72
5.67–11.33; 
47
>11.33; 39
# Pulmonary failure 
(ARDS)
# Renal failure (acute 
kidney injury)
# Shock
# Infected pancreatic 
necrosis
# Mortality
# Hospital stays
# ICU stays
Zhu, 201747 Pancreas CHN NA Jan 2005–Dec 2012 S 3203/3260 B, I, HL, A, O, (Mixed)
Revised 
Atlanta 
Classification
<11.33; 
2736
>11.33; 
467
# Mild, moderately 
severe and severe AP 
cases
# Mortality
Table 1. Characteristics of the studies included in the meta-analysis. Abbreviations: A, alcoholic; ALI, acute 
lung injury; AP, acute pancreatitis; APACHE II, acute physiology and chronic health evaluation; ARDS, acute 
respiratory distress syndrome; B, biliary; BISAP, bedside index for severity in acute pancreatitis; CHN, China; 
CT, computed tomography; D, overeating and/or high-fat diet; ESP, Spain; HTG, hypertriglyceridaemic; HUN, 
Hungary; I, idiopathic; ICU, intensive care unit; M, multicentre; NA, not available; NR, not relevant, because 
the data from AP severity were not used for the meta-analysis; O, others; P, prospective; pE, post- endoscopic 
retrograde cholangiopancreatography; R, retrospective; S, single-centre; SIRS, Systemic inflammatory response 
syndrome; SOFA, sequential organ failure assessment; seTG, serum triglyceride concentration; UK, United 
Kingdom; USA, United States of America. *The authors had access to the raw data in Párniczky et al. (2016)44 
because of the overlap between the authors. Therefore, it was possible to create new groups based on seTG 
which were not presented in the original publication (Supplementary Table S3).
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seTG. The comparison interventions were normal (<1.7), <5.6, 1.7–5.6, 1.7–11.3 and <11.3 mM seTG. Different 
outcomes were investigated: AP severity, mortality, pancreatic necrosis, persistent organ failure (POF) and 
multi-organ failure (MOF), pulmonary and renal failure, and admission to an intensive care unit (ICU).
Figure 2. The effects of seTG >1.7 and 1.7–11.3 mM vs. <1.7 mM on AP severity, mortality, pancreatic 
necrosis, pulmonary and renal failure, and persistent OF. (A) Forest plot shows the influence of seTG over 
1.7 mM compared with normal seTG (<1.7 mM). (B) The outcomes for the 1.7–11.3 mM seTG group were 
compared with those in patients with normal seTG (<1.7 mM). Filled rhombuses represent the risk ratio 
derived from the studies analysed. Horizontal bars represent 95% CI. Empty rhombuses show the overall effect 
(OR is the middle of the rhombus and CIs are the edges). The quality of studies was assessed by the Newcastle-
Ottawa Scale with the timing of the seTG measurement (for more details see Supplementary Table S2). 
Abbreviations: AP, acute pancreatitis; CI, confidence interval; Comp., comparability; NR, not relevant; meas., 
measurement; OF, organ failure; OR, odds ratio; seTG, serum triglyceride concentration.
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Article Search Strategy. The search was carried out in late August 2017. Observational prospective and 
retrospective cohorts, and case control studies were identified in Embase (published from 1948 to July 2017) 
and PubMed Library (published from 1961 to July 2017). Furthermore, ClinicalTrials.gov was also screened for 
additional unpublished data. The search contained the following terms for Embase: pancreatitis AND (‘triglycer-
ide’/exp OR triglyceride OR hypertriglyceridemia OR ‘hyperlipidemia’/exp OR ‘hyperlipidemia’) AND [english]/
lim AND (‘human’/de OR patient OR patients) NOT (‘conference abstract’/it OR ‘review’/it OR ‘case report’/de 
OR ‘nonhuman’/de OR ‘practice guideline’/de). The following terms were used for PubMed: pancreatitis AND 
(hyperlipidaemia OR hyperlipidemia OR triglycerides OR triglyceride OR hypertriglyceridaemia OR hypertri-
glyceridemia) AND (human OR patient OR patients) AND English NOT “case reports”[Publication Type]. The 
search terms for Clinicaltrials.gov were pancreatitis and hypertriglyceridemia.
Eligibility criteria. Articles were included if they fulfilled the following criteria:
 1. Case control or cohort studies.
 2. Studies involving AP patients.
 3. HTG (>1.7 mM) was present in at least one of the groups under investigation
 4. SeTGs were defined.
 5. Outcome data were provided for at least one of the following: severity of AP according to the revised Atlan-
ta Classification, mortality, pancreatic necrosis, POF, MOF, pulmonary failure, renal failure and intensive 
care unit (ICU) admission
 6. Written in English.
The seTG in different groups used as controls was below 1.7, 5.6 or 11.3 mM as well as within the 1.7–5.6 and 
1.7–11.3 mM ranges. Systematic reviews, meta-analyses, reviews, conference abstracts, letters, replies, reports, 
Figure 3. The effects of serum triglyceride concentration (seTG) at 1.7–5.6 mM and >5.6 mM vs. <1.7 mM on 
acute pancreatitis (AP) severity. (A) Forest plot shows the influence of 1.7–5.6 mM seTG compared with normal 
seTG (<1.7 mM). (B) The outcome of the >5.56mM seTG group was compared with the outcomes of patients 
with normal seTG (<1.7 mM). Filled rhombuses represent the risk ratio derived from the manuscripts analysed. 
Horizontal bars represent 95% CI. Empty rhombuses show the overall effect, odds ratio (OR) is the middle of 
the rhombus, and confidence intervals (CI) are the edges. The quality of studies was assessed by the Newcastle-
Ottawa Scale with the timing of the seTG measurement (for more details see Supplementary Table S2). 
Abbreviations: CI, confidence interval; Comp., comparability; NR, not relevant; meas., measurement; OR, odds 
ratio; seTG, serum triglyceride concentration.
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commentaries, notes, case studies, animal studies, practice guidelines and non-English-language (e.g. Chinese-, 
Polish- and German-language) articles were excluded from the analysis.
Data extraction and quality assessment of the articles included. Relevant studies were man-
ually screened by two independent researchers (LK and GF). The investigators read and selected the articles 
to be included in the statistical analysis and extracted the data. The Newcastle–Ottawa Scale (NOS) was used 
(Supplementary Table S2) to assess the quality of the articles included23,24. Since seTG decreases rapidly when 
food intake is restricted25, the NOS was supplemented with another scoring system in which the articles were also 
evaluated based on the timing of the seTG measurement (Supplementary Table S2).
Statistical analysis. The statistical analysis was performed with Stata 11 SE (StataCorp LLC, College Station, 
TX, USA). The numbers of patients with regard to AP severity, mortality, pancreatic necrosis, POF, MOF, pulmo-
nary failure, renal failure and ICU admission were used to calculate odds ratios (OR) to compare these outcomes 
in different seTG groups. ORs were pooled using the random effects model with the DerSimonien–Laird estima-
tion and displayed on forest plots. Summary OR estimation, p value and 95% Confidence Interval (CI) were cal-
culated. ORs with corresponding CIs and p values are indicated in the text according to the following order: OR 
[CI; p]. P < 0.05 was considered a significant difference from summary OR = 1. The different ORs were compared 
using the analysis of variance with random effect weights.
Heterogeneity and publication bias. Statistical heterogeneity was analysed using the I2 statistic and the chi-square 
test to acquire probability values; p < 0.05 was defined to indicate significant heterogeneity. The small-study effect 
was visually investigated on funnel plots.
Results
Study selection. The search for articles in three databases resulted in 2261 records (Fig. 1). After removing 
duplicates and screening titles and abstracts, 90 articles were assessed in full text for eligibility. Of these manu-
scripts, 29 prospective and retrospective cohorts seemed to be suitable for data collection. However, in 13 publica-
tions, seTGs were defined inappropriately (e.g.<1.88 mM was identified as normal) or the outcome data could not 
be used. Therefore, these 13 publications were removed from the assessment, and only 16 articles were included 
in the statistical analysis (in which the seTG ranges or the outcome data were appropriate). These studies were 
published between January 2000 and March 2016.
Figure 4. Forest plot showing the effect of seTG >11.33 mM vs. <1.7 mM on AP severity, mortality, persistent 
OF and the need for ICU. Filled rhombuses represent the risk ratio derived from the articles analysed. 
Horizontal bars represent 95% CI. Empty rhombuses show the overall effect (OR is the middle of the rhombus 
and CIs are the edges). The quality of studies was assessed by the Newcastle-Ottawa Scale with the timing of the 
seTG measurement (for more details see Supplementary Table S2). Abbreviations: AP, acute pancreatitis; CI, 
confidence interval; comp., comparability; ICU, intensive care unit; NR, not relevant; meas., measurement; OR, 
odds ratio; seTG, serum triglyceride concentration.
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Characteristics of studies. Both single- (13) and multicentre (3) cohort studies were included. Population 
sizes ranged from 43 to 3203, and six trials involved over 300 patients. The aetiology of AP was noted in all 
the studies, eight comprised HTG-AP (>11.3 mM seTG), and twelve contained alcoholic and biliary pancrea-
titis patients. Other aetiologies, such as post-ERCP, idiopathic, mixed and drug-induced AP, were also included 
in some articles. The studies were performed in the following countries: China (nine cohorts), the USA (three 
cohorts), Hungary (two cohorts), the UK (one cohort) and Spain (one cohort). Table 1 summarizes the charac-
teristics of the cohorts involved. During the quality assessment, we evaluated patient selection, comparability 
of the groups, outcome data, and the timing of the seTG measurement. These quality scores are depicted in the 
corresponding figures.
Clinical outcomes. Comparing the effects of HTG vs. normal seTG on the severity of AP. Different groups 
were created based on the extent of HTG, and the outcomes for AP were compared with those in the normal 
(<1.7 mM) seTG group. Figure 2A shows how HTG affects the course of AP. HTG significantly increased the 
number of severe AP cases (severity), pancreatic necrosis, persistent OF and renal failure compared to the 
non-HTG group (Fig. 2A). However, HTG did not significantly increase the odds for mortality and pulmonary 
failure compared to the <1.7 mM group. Analysing the effect of seTG in the range from 1.7 to 11.3 mM showed 
results similar to the previous comparison. The severity of AP and the incidence of POF significantly increased in 
the 1.7–11.3 mM range compared to the <1.7 mM seTG group, while it had no significant effect on the mortality 
of the patients (Fig. 2B). HTG was further divided into ranges of 1.7–5.6, >5.6 and >11.3 mM seTG. Figure 3A 
shows that the severity of AP was not significantly different in patients with 1.7–5.6 mM seTG compared to the 
<1.7 mM group. However, seTGs >5.6 mM significantly increased the risk for severe AP in patients with OR of 
2.01 [CI: 1.29–3.14; p = 0.002] compared to seTG <1.7 mM (Fig. 3B). The presence of severe and very severe 
HTG (>11.3 mM) markedly increased the severity of AP (OR = 3.08 [CI: 1.77–5.34; p = 0.000]), POF (OR = 2.39 
[CI: 1.45–3.95; p = 0.001]) and ICU admission (OR = 3.90 [CI: 2.53–6.00; p = 0.000]), but there was no significant 
elevation in mortality compared to the normal seTG group (Fig. 4). The OR values for AP severity showed an 
increasing trend (1.44 [CI: 0.92–2.25; p = 0.109]; 2.01 [CI: 1.29–3.14; p = 0.002]; 3.08 [CI: 1.77–5.34; p = 0.000]) 
in groups with HTG (1.7–5.6, >5.6 and >11.3 mM, respectively), compared to the reference group with seTG 
<1.7 mM (Figs 3 and 4, Table 2). Therefore, these results were compared statistically (Fig. 5). However, no signif-
icant differences (p = 0.108) were found between the three ORs.
The small-study effect was checked by placing the data acquired from articles on funnel plots (Supplementary 
Figs 1–3). A visual inspection of the funnel plots revealed no apparent asymmetry; therefore, we found no signs 
of the small-study effect.
Comparison 
intervention Intervention
Outcome OR [CI; p]
FigureAP Severity Mortality
Pancreatic 
necrosis Persistent OF Multiple OF
Pulmonary 
failure
Renal 
failure ICU admission
<1.7
>1.7
1.72 
[1.42–2.08; 
0.000]
1.40 [0.96–
2.06; 0.082]
1.60 [1.27–2.00; 
0.000]
1.84 [1.36–
2.49; 0.000]
4.45 [0.72–27.63; 
0.109]
3.91 
[1.03–14.84; 
0.045]
2A
1.7–11.3
1.65 
[1.19–2.30; 
0.003]
1.31 [0.86–
2.00; 0.214]
1.69 [1.22–
2.34; 0.001] 2B
1.7–5.6
1.44 
[0.92–2.25; 
0.109]
3A
>5.6
2.01 
[1.29–3.14; 
0.002]
3B
>11.3
3.08 
[1.77–5.34; 
0.000]
1.66 [0.93–
2.97; 0.088]
2.39 [1.45–
3.95; 0.001]
3.90 [2.53–6.00; 
0.000] 4
<5.6 >5.6
1.87 
[1.21–2.89; 
0.005]
2.75 [1.28–
5.92; 0.01]
4.23 [1.05–
17.11; 0.043]
3.74 
[2.14–6.52; 
0.000]
6A
1.7–5.6 >5.6
1.60 
[0.73–3.51; 
0.245]
6B
<11.3 >11.3
1.66 
[1.28–2.16; 
0.000]
1.64 [1.11–
2.44; 0.014]
2.28 [1.62–3.21; 
0.000]
1.55 [0.75–
3.22; 0.236]
3.11 [2.20–4.39; 
0.000] 7
1.7–11.3 >11.3
1.5 
[0.88–2.54; 
0.132]
1.34 [0.71–
2.55; 0.366]
1.41 [0.87–
2.28; 0.166] 8
Table 2. Summary of the groups compared based on seTG. Bold cells indicate significant differences between 
the groups (p < 0.05), Italic cells show no significant difference (p > 0.05), and empty cells stand for no 
comparison for that outcome. Under outcomes, the numbers in bold indicate the OR values and square brackets 
contain CI and p values for the respective comparisons. Abbreviations: AP, acute pancreatitis; CI, confidence 
interval; ICU, intensive care unit; OF, organ failure.
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The effect of different ranges of HTG on AP. If seTG is elevated, the extent of the increase could also have an 
impact on the course of AP. Comparing the effect of seTG below and above 5.6 mM showed that seTG higher 
than 5.6 mM significantly increased the risk for severe AP, mortality, and pulmonary and renal failure (Fig. 6A). 
However, the severity of AP was not significantly different in HTG patients with seTG of 1.7–5.6 mM vs. >5.6 mM 
(Fig. 6B). Severe and very severe HTG (>11.3 mM seTG) significantly increased the OR of severe AP, mortality, 
pancreatic necrosis and ICU admission compared to group with seTG < 11.3 mM, but it did not influence the 
occurrence of MOF (Fig. 7). Interestingly, when the effect of severe and very severe HTG was compared with 
mild and moderate HTG (seTG 1.7–11.3 mM), no significant difference was revealed between the two groups 
with regard to AP severity, mortality and POF (Fig. 8). All the groups compared on the basis of seTG are summa-
rized in Table 2. The data extracted from articles were depicted on funnel plots to test for the small-study effect 
(Supplementary Figures 4–6). Visual inspection of the funnel plots showed no evident asymmetry; therefore, we 
found no signs of the small-study effect.
Discussion
In this study, we investigated the effect of different seTGs on the outcome of AP. HTG worsens the course of AP 
compared to the normal seTG group. However, an increase in seTG up to 5.6 mM did not significantly influence 
the severity of AP. Selecting subgroups within HTG (>5.6; >11.3 mM) resulted in a significant elevation of ORs 
(2.01 and 3.08, respectively) for severity when all the groups were compared with the effect of normal seTG on 
AP severity. These data suggest that HTG aggravates the course of AP. Our findings are in line with earlier animal 
studies, in which hyperlipidaemia increased the severity of AP26–30.
The underlying mechanism by which HTG exacerbates the severity of AP is unknown. One of the possible 
processes is that pancreatic lipases metabolize seTG to non-esterified fatty acids (NEFA)31,32. These NEFA are 
toxic and cause MOF to worsen the outcome of AP33–36. The administration of NEFA induced sustained elevation 
of [Ca2+] in pancreatic acinar cells and inhibited mitochondrial function and ATP production37,38. Consequently, 
NEFAs cause damage to acinar and vascular endothelial cells, thus leading to inflammation39. Our earlier studies 
have also indicated that fatty acids inhibit CFTR activity and decrease the HCO3− and fluid secretion of pancre-
atic ductal cells40,41. In addition, in the case of HTG, the concentration of chylomicrons is elevated. This increases 
blood viscosity, which impairs blood flow and results in pancreatic ischemia and acidosis31,32. Since AP is not 
induced in all patients with HTG10, we assume that other factors also contribute to the development of AP.
Interestingly, the mortality of patients did not show statistically significant differences between groups 
(Figs. 2–4; p values: 0.082; 0.214; 0.088), which is likely to be the result of the small number of patients with this 
outcome. The odds for complications (SIRS, POF, involving pulmonary, renal, and circulatory failure) were signif-
icantly increased in groups with HTG. Although mortality is related to disease complications, the results from the 
Figure 5. The effects of seTG of 1.7–5.6, >5.6 and >11.3 mM vs. <1.7 mM on AP severity. The difference 
between ORs in seTG subgroups (1.7–5.6, >5.6 and >11.3 mM) were compared. The probability value for the 
difference in OR was 0.108 after the analysis.
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statistical analysis for mortality were not in line with the outcomes for AP (e.g. severity, POF, necrosis). Therefore, 
further investigation of HTG-AP would be beneficial with respect to mortality.
Although there is no unanimous definition for HTG-AP, it is widely accepted that AP with seTG >11.3 mM 
is HTG-related12. However, some researchers consider HTG-AP to be defined by a seTG threshold >5.6 mM10. 
Therefore, this encouraged us to investigate the relationships between the extent of HTG and the outcome of AP 
(Figs. 6–8). SeTG > 5.6 mM significantly worsened the outcomes for AP when compared with the seTG < 5.6 mM 
group, while there was no difference when seTG > 5.6 mM was compared with seTG in the 1.7–5.6 mM range 
(p value: 0.245). Similar results were seen at a cut-off seTG of 11.3 mM. SeTG > 11.3 mM caused more severe 
AP than seTG < 11.3 mM, but when the effect of seTG > 11.3 mM was compared with that of seTG in the 1.7–
11.3 mM range, no significant difference was seen between the two groups (p values: 0.132; 0.366; 0.166). These 
comparisons also support our previous assumption that compared to normal seTG, HTG is associated with an 
increased risk for severe AP and complications. However, we could not detect any significant differences in AP 
severity based on the degree of HTG. Further studies would be important to clarify the relationship between the 
extent of HTG and the severity of AP.
Figure 6. Forest plot showing the effect of seTG >5.6 mM vs. <5.6 or 1.7–5.6 mM on AP severity, mortality, 
and pulmonary and renal failure. (A) Forest plot shows the influence of seTG over 5.6 mM compared with that 
of seTG <5.6 mM. (B) The AP severity in the > 5.6 mM seTG group was compared with that in patients with 
seTG in the 1.7–5.6 mM range. Filled rhombuses represent the risk ratio derived from the articles analysed. 
Horizontal bars represent 95% CI. Empty rhombuses show the overall effect (OR is the middle of the rhombus 
and CIs are the edges). The quality of studies was assessed by the Newcastle-Ottawa Scale with the timing of the 
seTG measurement (for more details see Supplementary Table S2). Abbreviations: AP, acute pancreatitis; CI, 
confidence interval; comp., comparability; NR, not relevant; meas., measurement; OR, odds ratio; seTG, serum 
triglyceride concentration.
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Most of the earlier attempts to investigate the effect of HTG on the severity of AP via meta-analysis were 
unsuccessful due to the small number of available observational studies10,14, except for Wang et al.13, which was 
published last year after our PROSPERO registration. It analysed 14 articles, five of which overlapped with stud-
ies included in our paper13. A careful look at Wang et al.13 revealed that inconsistent data and grouping abound. 
Two groups were defined for the comparisons, the TG-related AP (TGAP) group and the non-TG-related AP 
(NTGAP) group. The patients categorized as TGAP had seTG > 11.3 mM or >5.6mM with a previous history 
of HTG. Otherwise, patients were categorized into the NTGAP group. However, we are unsure how this catego-
rization relates to their statistical analysis because in some of the articles involved the seTGs were classified as 
<2.26 or <1.7 mM and used for the NTGAP group, and the TGAP group contained patients with seTG > 2.26 or 
>1.7 mM. For example, Nawaz et al.15 had 115 patients with normal (<1.7 mM) seTG who were included in the 
NTGAP group, while the 86 patients with HTG (seTG > 1.7 mM) were listed in the TGAP group. Another exam-
ple of this discrepancy could be found in Fig. 2 in their article13, where Zeng et al. (2014) involved groups with 
seTG < 1.7 (NTGAP) and ≥5.65 mM (TGAP), Yin et al. (2015) consisted of groups with seTG < 5.6 (NTGAP) 
and >5.6 mM (TGAP), Tariq et al. (2016) contained groups with seTG < 2.27 (NTGAP) and ≥2.27 mM (TGAP), 
and Jiang et al. (2005) comprised groups with seTG < 1.7 (NTGAP) and >1.7 mM (TGAP). However, all these 
different elevations of seTG were used within one analysis. Furthermore, some errors could also be identified for 
the patient numbers used for the analysis (e.g. in Fig. 2, the patients with NTGAP in Huang et al. (2014) should 
be 4/828 instead of 4/1459). Thus, Wang et al.13 compared two groups of patients, one with seTG > 1.7 mM and 
one with seTG < 5.65 mM, where the two groups overlap between 1.7 and 5.65 mM seTG. The authors proved that 
the AP group with higher seTG had an increased risk for systemic complications and an elevated mortality rate 
compared to patients with lower seTG. Our results partly confirm the findings from Wang et al.13.
In 2016 and 2017, eight well-written articles17,18,42–47 were published in which the effect of HTG on the severity 
of AP was investigated, and this allowed us to prepare a meta-analysis by combining those cohorts with those in 
earlier papers. However, our study has several limitations: (1) Although the literature is more extensive nowadays, 
most of our analyses contained a small number of articles (generally 3–5 studies). (2) The different populations 
(China or the USA) and the various baseline data (e.g. body mass index, age and sex) could represent a bias. (3) 
Aetiologies (biliary or alcoholic) for AP differ. (4) Only English-language articles were included in this study, 
which can affect the results. (5) There were no statistical significances for all the investigations even if the ORs 
Figure 7. Forest plot showing the effect of seTG >11.3 mM vs. <11.3 on AP severity, mortality, pancreatic 
necrosis, the need for ICU admission and multiple OF. Filled rhombuses represent the risk ratio derived from 
the articles analysed. Horizontal bars represent 95% CI. Empty rhombuses show the overall effect (OR is the 
middle of the rhombus and CIs are the edges). The quality of studies was assessed by the Newcastle-Ottawa 
Scale with the timing of the seTG measurement (for more details see Supplementary Table S2). Abbreviations: 
AP, acute pancreatitis; CI, confidence interval; comp., comparability; ICU, intensive care unit; NR, not relevant; 
meas., measurement; OF, organ failure; OR, odds ratio; seTG, serum triglyceride concentration.
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were high (e.g. OR = 4.45 with p value of 0.109). A further increase in the number of articles and patients could 
clarify any discrepancies related to ORs or significance. (6) Meng et al.48 observed significant differences (more 
than ±10%) between the seTG values obtained using various commercially available kits. (6) Significant heter-
ogeneities were detected for some analyses. (7) Notably, seTG changes dynamically, which relates to food intake 
and fasting. Current treatment protocols for most AP patients include fasting at the beginning of hospitalization, 
except for suspected severe AP cases where early enteral feeding (within 48 hours) is recommended49,50. Fasting 
results in a rapid (within 48 hours) drop of seTG10 and measuring seTG 48 or 72 hours after the admission might 
underrepresent levels at the onset of AP. Dominguez-Munoz et al.25 demonstrated a dramatic decrease in seTG 
during fasting: seTG falls from approx. 30 mM to 5 mM within three days. Other authors also confirmed this 
phenomenon2,10,51. To take this bias into account, we scored the articles based on the timing of the seTG meas-
urement. Having high scores for NOS and seTG measurement timing represents good quality for the selection of 
articles for this meta-analysis.
Figure 8. Forest plot showing the effect of seTG >11.3 mM vs. 1.7–11.3 on AP severity, mortality and persistent 
OF. Filled rhombuses represent the risk ratio derived from the articles analysed. Horizontal bars represent 
95% CI. Empty rhombuses show the overall effect (OR is the middle of the rhombus and CIs are the edges). 
The quality of studies was assessed by the Newcastle-Ottawa Scale with the timing of the seTG measurement 
(for more details see Supplementary Table S2). Abbreviations: AP, acute pancreatitis; CI, confidence interval; 
comp., comparability; NR, not relevant; meas., measurement; OF, organ failure; OR, odds ratio; seTG, serum 
triglyceride concentration.
Figure 9. Schematic diagram shows the effect of normal seTG and HTG on the severity and complications of 
AP. Abbreviations: HTG, hipertriglyceridemia; seTG, serum triglyceride concentration.
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To improve the design of further retrospective or prospective cohorts related to HTG-AP, we would suggest 
some recommendations. It is advisable to keep the time interval for the seTG measurement consistent. Preferably, 
it should be performed within 48 hours after the onset of the first symptoms and repeated regularly. Publishing 
the medical history of patients with respect to seTG-lowering therapies would also be advantageous, e.g. describ-
ing the regular use of statins or fibrates, which could decrease the incidence of AP52. If patients have HTG on 
admission for AP, then lipid-lowering therapy (such as plasmapheresis) is recommended according to guidelines. 
The use of these therapies would also improve further studies. Due to large differences between the kits used for 
seTG determination, standardizing the method for seTG measurement is also recommended. Based on basic 
discoveries, cohort analyses, clinical studies and meta-analyses, early intervention (e.g. heparin and/or insulin 
therapies and plasmapheresis) to normalise HTG may be beneficial for patients, and this should be investigated 
in randomised controlled trials.
In conclusion, HTG worsens the severity of AP and increases the risk for local and systemic complications 
(Fig. 9). However, there was no difference in AP severity based on the extent of HTG53.
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